The last few days has seen a number of events in the Boston Biotech Cluster which have involved women executives. Here is our pick of the top 5:
- Annalisa Jenkins: Leads Dimension Therapeutics to an IPO and gets names as Fierce Woman of 2015.
Annalisa Jenkins has been making a splash ever since her arrival at Dimension Therapeutics and following a very rapid assimilation to the world of small biotech, she has built on her early successes in progressing the gene therapy technology towards the clinic and building a diverse team, by taking the company public. With a deal in place with Bayer and strong private financing from Fidelity, Annalisa and her newly assembled team pulled off a $71.5m IPO in what is best described as a tumultuous public market.
- Marsha Fanucci: Appointed to the Board of Directors at Syros.
Marsha Fanucci has joined up with another ex-Millennium Pharmaceuticals colleague to join the board of directors at Syros Pharmaceuticals. The company, run by Nancy Simonian, works in the area of gene control. Marsha Fanucci currently occupies board seats at other prominent biotech companies, Alnylam, Ironwood, FORMA Therapeutics and Ironwood Pharmaceuticals. Marsha was formerly CFO and SVP Strategy at Millennium Pharmaceuticals.
- Samantha Singer: Named a Fierce BioPharma Woman 2015.
Samantha Singer who left Biogen to join the Board Institute received recognition by industry news site Fierce Biotech, as a Top BioPharma Women for 2015. The yearly publication of the list has provided some stand-out names in the past. Speaking to Fierce Biotech, Samantha Singer said: “Leadership is about creating futures that are not a direct path. It’s about being courageous and being willing to speak about and talk about futures that aren’t obvious to other people. Take a stand for a future you can see, one you know can happen even when you can’t see how.”
- Adelene Perkins: Appointed to the Board of Directors at Padlock Therapeutics as first independent Director.
Padlock Therapeutics, run by Atlas Venture Partner, Michael Gillman, announced the appointment of Adelene Perkins to the board of directors. This was the first appointment of an independent director. Adelene, President and CEO of Infinity Pharmaceuticals, also was given an accolade by the Boston Globe, making a list of Massachusetts Top Business Women, in fact, she was the only Biotech Executive to make the list.
- Vanessa King: Renames company Luc Therapeutics and strikes a deal with Novartis
Vanessa is CEO of the newly named Luc Therapeutics and after receiving a positive reception for the new name on social media, the company quickly got back to business and cemented terms on a deal with pharma; Novartis on this occasion. Under the terms of the deal, Luc has exclusively licensed to Novartis intellectual property for compounds that selectively negatively modulate NR2B-containing NMDA receptors. Novartis will fund all research and development for the program. Deal terms include an upfront payment to Luc, as well as development and sales milestones and royalties.